Large-Scale Cohort Study Identifies Sociodemographic Disparities in Post-Cancer Accelerated Aging

A retrospective study of 109,224 Danish cancer survivors shows that therapy-related accelerated aging is exacerbated by social determinants of health, particularly lower educational attainment.

Researchers conducted a retrospective cohort study using Danish national registries to evaluate 109,224 curatively treated cancer survivors (diagnosed with lung, breast, prostate, or colon cancer between 1997 and 2018) and 574,022 age- and sex-matched cancer-free controls.

During a median 6.9-year follow-up, cancer survivors exhibited significantly higher rates of 16 post-cancer morbidities compared to controls, with lung and colon cancer survivors exhibiting elevated hazard rates for 14 morbidities, breast cancer survivors for 12, and prostate cancer survivors for 8.

The study evaluated social determinants of health (SDOH) using educational level and cohabitation status, finding significant disparities among survivors.

Survivors with short education experienced higher hazard rates for chronic respiratory disease (HRs: 1.30 to 1.55 across cancer types), heart failure (HRs: 1.50 to 1.54 in breast and colon), diabetes (HRs: 1.67 to 1.95 in breast, prostate, and colon), and depression (HRs: 1.32 to 1.37 in breast and colon).

Living alone was also associated with increased morbidity rates, though the association was less pronounced than that of educational level.

The findings indicate that while curative cancer treatments extend survival, they are associated with accelerated biological aging that manifests as elevated rates of chronic, age-related morbidities.

It establishes that clinical outcomes in post-treatment survivorship are not determined solely by biological or medical interventions, but are heavily moderated by socioeconomic factors and educational attainment.

This emphasizes the complexity of managing accelerated aging in heterogeneous clinical populations, indicating a need for multi-factorial clinical assessment tools.

Longevity medicine and clinical survivorship programs may need to pivot toward multidisciplinary care structures that actively integrate social determinants of health into risk-stratification protocols.

Therapeutic developers targeting treatment-induced accelerated aging, such as senolytics or metabolic regulators, may face regulatory and clinical trial design pressures to ensure study cohorts are representative of diverse socioeconomic backgrounds, as these variables significantly influence primary morbidity endpoints.

Whether clinical guidelines for post-cancer survivorship care begin incorporating sociodemographic risk profiling to implement targeted preventative interventions.